These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
364 related items for PubMed ID: 14752247
41. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T, Kurita N, Fukuma S, Akizawa T, Fukuhara S. Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541 [Abstract] [Full Text] [Related]
42. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Rix M, Eskildsen P, Olgaard K. Nephrol Dial Transplant; 2004 Apr; 19(4):870-6. PubMed ID: 15031343 [Abstract] [Full Text] [Related]
43. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. Al-Hilali N, Al-Humoud H, Al-Helal B, Al-Azmi M, Al-Kandari NH, Johny KV. Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162 [Abstract] [Full Text] [Related]
46. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone. Jean G, Mayor B, Hurot JM, Deleaval P, Lorriaux C, Zaoui E, Chazot C. Nephrol Dial Transplant; 2013 Jan; 28(1):176-82. PubMed ID: 22764192 [Abstract] [Full Text] [Related]
48. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM, en nombre de los investigadores del estudio OSERCE. Nefrologia; 2013 Jan 18; 33(1):46-60. PubMed ID: 23364626 [Abstract] [Full Text] [Related]
49. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover. Shigematsu T, Kawaguchi Y, Kubo H, Nakayama M, Kato N, Yamamoto H, Osaka N, Hayakawa H, Ogawa A, Sakai O. Adv Perit Dial; 1996 Jan 18; 12():250-6. PubMed ID: 8865914 [Abstract] [Full Text] [Related]
50. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. Arenas MD, Alvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Nuñez C, Devesa R, Albiach B. J Nephrol; 2007 Jan 18; 20(4):453-61. PubMed ID: 17879212 [Abstract] [Full Text] [Related]
59. Vitamin D treatment in hemodialysis patients with low serum levels of parathyroid hormone: which is the best choice? Lomonte C, Casucci F, Libutti P, Losurdo N, Teutonico A, Basile C. J Nephrol; 2010 Apr 18; 23(2):210-5. PubMed ID: 20175051 [Abstract] [Full Text] [Related]
60. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Toussaint N, Boddington J, Simmonds R, Waldron C, Somerville C, Agar J. Hemodial Int; 2006 Jul 18; 10(3):280-6. PubMed ID: 16805890 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]